These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37646524)

  • 41. Whole Genome Sequencing for the Analysis of Drug Resistant Strains of
    Nieto Ramirez LM; Quintero Vargas K; Diaz G
    Antibiotics (Basel); 2020 Mar; 9(3):. PubMed ID: 32209979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bedaquiline resistant Mycobacterium tuberculosis clinical isolates with and without rv0678 mutations have similar growth patterns under varying BDQ drug pressure.
    Saeed DK; Ashraf J; Hasan Z; Shakoor S; Kanji A; Hasan R
    Tuberculosis (Edinb); 2022 Dec; 137():102266. PubMed ID: 36195000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of drug resistance profile of multidrug-resistant Mycobacterium tuberculosis (MDR-MTB) isolates from newly diagnosed case by whole genome sequencing (WGS): a study from a high tuberculosis burden country.
    Sun W; Gui X; Wu Z; Zhang Y; Yan L
    BMC Infect Dis; 2022 May; 22(1):499. PubMed ID: 35624432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
    Gómez-González PJ; Perdigao J; Gomes P; Puyen ZM; Santos-Lazaro D; Napier G; Hibberd ML; Viveiros M; Portugal I; Campino S; Phelan JE; Clark TG
    Sci Rep; 2021 Sep; 11(1):19431. PubMed ID: 34593898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiology of Nontuberculous Mycobacteria in Nanjing and
    Zhang R; Luo S; Wang N; Zhang H; Wu X
    Infect Drug Resist; 2023; 16():2751-2764. PubMed ID: 37180636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
    Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
    Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
    Battaglia S; Spitaleri A; Cabibbe AM; Meehan CJ; Utpatel C; Ismail N; Tahseen S; Skrahina A; Alikhanova N; Mostofa Kamal SM; Barbova A; Niemann S; Groenheit R; Dean AS; Zignol M; Rigouts L; Cirillo DM
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32907992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs.
    Wu SH; Xiao YX; Hsiao HC; Jou R
    Microbiol Spectr; 2022 Dec; 10(6):e0260522. PubMed ID: 36255328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.
    Liu Y; Shi J; Li L; Wu T; Chu P; Pang Y; Guo Y; Gao M; Lu J
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0053122. PubMed ID: 36448833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination.
    Du J; Gao J; Yu Y; Li Q; Bai G; Shu W; Gao M; Liu Y; Wang L; Wang Y; Xue Z; Huo F; Li L; Pang Y
    Front Microbiol; 2021; 12():655653. PubMed ID: 34012425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bedaquiline: Current status and future perspectives.
    Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H
    J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis.
    An Q; Lin R; Yang Q; Wang C; Wang D
    J Glob Antimicrob Resist; 2023 Sep; 34():214-226. PubMed ID: 37172764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
    J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
    Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
    J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
    Pitso L; Potgieter S; Van der Spoel van Dijk A
    S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy.
    Chauffour A; Lounis N; Andries K; Jarlier V; Veziris N; Aubry A
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011379. PubMed ID: 38011249
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Perumal R; Khan A; Naidoo K; Ngema SL; Nandlal L; Padayatchi N; Dookie N
    Infect Drug Resist; 2023; 16():2849-2859. PubMed ID: 37193296
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.